These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 6391662)
1. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662 [TBL] [Abstract][Full Text] [Related]
2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
3. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
5. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534 [TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205 [TBL] [Abstract][Full Text] [Related]
7. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220 [TBL] [Abstract][Full Text] [Related]
8. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
10. [Results with the use of the M-2 protocol in plasmacytoma]. Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811 [TBL] [Abstract][Full Text] [Related]
11. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076 [TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients]. Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100 [TBL] [Abstract][Full Text] [Related]
14. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535 [TBL] [Abstract][Full Text] [Related]
15. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
17. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma]. Paule B; Quillard J; Bisson M; Massias P Nouv Rev Fr Hematol (1978); 1987; 29(6):391-6. PubMed ID: 2454453 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)]. Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590 [No Abstract] [Full Text] [Related]
19. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]